Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Next-generation IO medicine with significant potential to benefit patients into the next decade Today Near-Term Future Opdualag TM 2/3L+ MSS Colorectal Cancer & Adjuvant melanoma Strong launch supporting rapidly expanding dual 10 option for 1L melanoma patients Phase 3 trials ongoing Non-Small Cell Lung Cancer & Hepatocellular Carcinoma Phase 2 trials underway to inform path forward Ill Bristol Myers Squibb™ Not for Product Promotional Use 98

View entire presentation